Stock Financial Ratios, Dividends, Split History

AT / Atlantic Power Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.15
Volume233,700.00
Market Cap ($M)241.80
Enterprise Value ($M)538.47
Book Value ($M)-12.70
Book Value / Share-0.11
Price / Book-18.60
NCAV ($M)-771.70
NCAV / Share-6.86
Price / NCAV-0.31
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 115,100,000
Weighted Average Number Of Shares Outstanding Basic 115,100,000
Common Shares Outstanding 116,008,834
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets1,113.10
Liabilities918.50
Quick Ratio1.13
Current Ratio1.26
Income Statement (mra) ($M)
Revenues98,400,000.00
Net Income-93.00
Cash Flow Statement (mra) ($M)
Cash From Operations169.20
Cash from Investing2.80
Cash from Financing2.80
Identifiers and Descriptors
CUSIP04878Q863
Central Index Key (CIK)1419242
Related CUSIPS
04878Q903 04878Q953

Split History

Stock splits are used by Atlantic Power Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Ameren's Arm Set to Acquire 400 MW Wind Farm in Missouri

2018-05-23 zacks
Ameren Corporation’s (AEE - Free Report) subsidiary, Ameren Missouri, recently announced that it has signed an agreement for acquiring a 400-megawatt (MW) wind farm in northeast Missouri. Notably, Ameren Missouri will purchase the farm following its construction. The transaction seems to be in line with the company’s goal to reduce carbon emissions up to 80% by 2050. Details of the Agreement The wind farm will consist of 175 technologically-advanced wind turbines and electricity generated from these turbines will be sufficient enough to power an estimated 120,000 homes by 2020. (28-0)

Public Service Enterprise Gets Nod for Gas System Upgrade

2018-05-23 zacks
Public Service Enterprise Group Inc.’s (PEG - Free Report) subsidiary, Public Service Electric and Gas Company (PSE&G), recently got the regulatory go-ahead to start operations for the next phase of its Gas System Modernization Program (GSMP II). The approval for the multi-party settlement was granted by the New Jersey Board of Public Utilities (BPU). Under GSMP II program, the company plans on investing $1. (9-0)

COPEL (ELP) Q1 Earnings Decline Y/Y, High Expenses a Drag

2018-05-16 zacks
Companhia Paranaense de Energia – COPEL reported weak results in the first quarter of 2018. The Brazilian utility’s net income decreased 18.6% year over year to R$339.6 ($104.5 million). The company’s earnings per share were R$1.21, down 19% from the year-ago tally of R$1.50. The American Depository Receipt (ADR) equivalent for the reported quarter was 37 cents while earnings in the year-ago quarter were 48 cents. (9-0)

Why Atlantic Power (AT) Might Be a Diamond in the Rough

2018-05-11 zacks
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach. So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision. One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Atlantic Power Corporation (AT - Free Report) . (367-0)

Atlantic Power Corp's (AT) CEO Jim Moore on Q1 2018 Results - Earnings Call Transcript

2018-05-04 seekingalpha
Atlantic Power Corporation (NYSE:AT) Q1 2018 Results Earnings Conference Call May 4, 2018 8:30 AM ET (3-0)

CUSIP: 04878Q863